Recent advance in tenecteplase in acute ischemic stroke reperfusion
10.3760/cma.j.cn115354-20240624-00375
- VernacularTitle:替奈普酶在急性缺血性卒中再灌注治疗中的研究进展
- Author:
Yao ZHAO
1
;
Hailong ZHONG
Author Information
1. 惠州市第一人民医院脑血管病科，惠州 516000
- Keywords:
Tenecteplase;
Acute ischemic stroke;
Reperfusion;
Intravenous thrombolysis;
Endovascular thrombectomy
- From:
Chinese Journal of Neuromedicine
2024;23(10):1050-1054
- CountryChina
- Language:Chinese
-
Abstract:
Stroke has the highest morbidity and mortality in the adults of China, with heavy burden to the society and family. In recent years, the third generation of thrombolytic drug tenecteplase has made breakthrough in many fields of acute ischemic stroke reperfusion, and has been recommended by domestic and foreign guidelines for intravenous thrombolysis or intravenous thrombolysis bridging to mechanical thrombectomy for acute ischemic stroke. Results of several large clinical trials of tenecteplase have been published in the European Stroke Organization Conference in 2024, which provides more evidence-based medical evidences for tenecteplase in acute ischemic stroke reperfusion. This article reviews the latest research on tenecteplase in acute ischemic stroke reperfusion, and looks forward to the future direction of this field, in order to provide some references for clinicians and further related clinical study using tenecteplase.
